Wordt geladen...
Open-Label Trial of Ranolazine for the Treatment of Paramyotonia Congenita
INTRODUCTION: Paramyotonia congenita (PMC) is a non-dystrophic myotonic disorder that is believed to be caused by a defect in Na(v)1.4 sodium channel inactivation. Ranolazine, which acts by enhancing slow inactivation of sodium channels, has been proposed as a therapeutic option, but in vivo studies...
Bewaard in:
| Gepubliceerd in: | Muscle Nerve |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6340713/ https://ncbi.nlm.nih.gov/pubmed/30390395 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mus.26372 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|